Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Cash from Investing Activities (2019 - 2026)

Enliven Therapeutics has reported Cash from Investing Activities over the past 8 years, most recently at $42.5 million for Q1 2026.

  • Quarterly results put Cash from Investing Activities at $42.5 million for Q1 2026, up 2880.1% from a year ago — trailing twelve months through Mar 2026 was -$132.7 million (down 695.58% YoY), and the annual figure for FY2025 was -$173.8 million, down 382.93%.
  • Cash from Investing Activities reached $42.5 million in Q1 2026 per ELVN's latest filing, up from $12.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $42.5 million in Q1 2026 and bottomed at -$183.6 million in Q2 2025.
  • Median Cash from Investing Activities over the past 5 years was -$101000.0 (2022), compared with a mean of -$18.6 million.
  • Peak annual rise in Cash from Investing Activities hit 38402.97% in 2023, while the deepest fall reached 253821.43% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$101000.0 in 2022, then skyrocketed by 38402.97% to $38.7 million in 2023, then tumbled by 98.12% to $727000.0 in 2024, then surged by 1602.75% to $12.4 million in 2025, then surged by 243.53% to $42.5 million in 2026.
  • Business Quant data shows Cash from Investing Activities for ELVN at $42.5 million in Q1 2026, $12.4 million in Q4 2025, and -$4.1 million in Q3 2025.